Iridex Corporation filings document an ophthalmic medical technology issuer whose disclosures center on laser systems, delivery devices, consumables, and procedure probes for glaucoma and retinal disease applications. Form 8-K reports furnish operating and financial results, preliminary results, Regulation FD investor materials, material agreements, and other material-event disclosures.
Proxy materials describe board matters, executive compensation, equity award valuation adjustments, and pay-versus-performance information. The filing record also includes Nasdaq continued-listing compliance updates, capital-structure context such as stockholders’ equity requirements, exhibits to press releases and presentations, and Inline XBRL cover-page data for formal Exchange Act reporting.
IRIDEX CORP Chief Financial Officer Romeo R. Dizon reported open-market purchases of the company’s common stock. On January 20, 2026, he bought 2,100 shares at a price of $1.4987 per share. On January 21, 2026, he made two additional purchases of 409 shares at $1.53 per share and 1,750 shares at $1.49 per share.
After these transactions, Dizon directly owned 100,440 shares of IRIDEX common stock. The filing indicates these holdings are reported as directly owned, with no indirect ownership relationships noted.
Iridex Corp’s chief financial officer, Romeo R. Dizon, reported multiple acquisitions of the company’s common stock. On January 16, 2026, he acquired several small lots of shares at prices ranging from $1.38 to $1.45 per share, each coded as an acquisition transaction.
After these trades, his directly held beneficial ownership in Iridex common stock was reported at 96,181 shares. All reported holdings are shown as directly owned in his name.
IRIDEX Corporation reported that it has released preliminary, unaudited results for its fourth fiscal quarter and full fiscal year ended January 3, 2026. The company shared these operational and financial figures in a press release dated January 12, 2026, which is attached as Exhibit 99.1. The disclosure is being furnished rather than filed, meaning it is not automatically incorporated into other securities law filings unless specifically referenced.
IRIDEX Corporation reported an insider share issuance involving a major holder. On 01/02/2026, Novel Inspiration International Co., Ltd., a 10% owner, received 116,540 shares of IRIDEX common stock at a stated price of $0 per share as reflected in the Form 4.
The filing explains that these shares were issued as a quarterly interest payment on a Convertible Promissory Note dated March 19, 2025 between IRIDEX and Novel Inspiration. After this transaction, Novel Inspiration is shown as beneficially owning 351,483 shares of IRIDEX common stock. The Form 4 is filed jointly by Novel Inspiration and Shih‑Yao David Lin, who is the sole officer, director and stockholder of Novel Inspiration, while the shares are owned directly by Novel Inspiration.
IRIDEX CORP’s 10% owner Novel Inspiration International Co., Ltd. reported receiving additional common shares. On 10/01/2025, Novel Inspiration acquired 97,610 shares of IRIDEX common stock at a reported price of $0.0000 per share, increasing its beneficial ownership to 234,943 shares held directly.
The shares were issued as a quarterly interest payment on a Convertible Promissory Note that IRIDEX had issued to Novel Inspiration on March 19, 2025. The Form 4 is filed jointly by Novel Inspiration and Shih-Yao David Lin, who is the sole officer, director and stockholder of Novel Inspiration, while the shares themselves are owned directly by Novel Inspiration.
IRIDEX Corp reported an insider ownership change involving a major shareholder. On July 1, 2025, Novel Inspiration International Co., Ltd., identified as a 10% owner of IRIDEX (IRIX), was issued 137,333 shares of common stock.
The Form 4 states that these shares were issued as a quarterly interest payment on a Convertible Promissory Note dated March 19, 2025 between IRIDEX and Novel Inspiration. The shares were received at a stated price of $0.00 per share, and the filing shows 137,333 shares beneficially owned following the transaction, held directly by Novel Inspiration.
The report is filed jointly by Novel Inspiration and Shih-Yao David Lin, who is described as the sole officer, director and stockholder of Novel Inspiration, linking his interests to this 10% ownership position.
IRIDEX Corp reported that Novel Inspiration International Co., Ltd. and Shih‑Yao David Lin are 10% owners via preferred stock and a convertible note. As of March 19, 2025, Novel Inspiration held 600,000 shares of Series B Preferred Stock and a convertible promissory note convertible into 400,000 additional Series B Preferred shares, all owned directly by Novel Inspiration.
Each Series B Preferred share is convertible, at Novel Inspiration’s option, into five shares of common stock with no expiration date, representing 3,000,000 common shares from the existing preferred and a further 2,000,000 common shares from the note. Before required stockholder approval, Novel Inspiration could convert only into 3,356,126 common shares, equal to 19.99% of IRIDEX’s outstanding common stock as of March 19, 2025, and that approval was obtained on June 11, 2025.
Novel Inspiration International Co., Ltd. and Shih‑Yao David Lin report beneficial ownership of 5,351,483 IRIDEX Corporation shares, or 24.1% of the common stock. Their position comes from 600,000 shares of Series B Preferred Stock purchased at $10.00 per share and a $4,000,000 convertible promissory note, both convertible into a total of 5,000,000 common shares, plus 351,483 common shares issued as interest on the note. The note carries 12% annual interest, payable quarterly in common stock based on a formula tied to market price and a minimum price of $0.21 per share.
Novel Inspiration and Mr. Lin describe the investment as for investment purposes but indicate plans to engage with IRIDEX’s board and management on strategy, capital structure, and potential transactions, including possible mergers, acquisitions, or a going‑private deal. An Investor Rights Agreement gives Novel Inspiration registration rights, the ability—subject to ownership thresholds—to appoint up to two directors, and approval rights over certain corporate actions, increasing their potential influence over the company’s governance and strategic direction.
IRIDEX Corporation director reports open-market stock purchase
A director of IRIDEX Corporation reported buying 2,000 shares of common stock on 12/16/2025 at a price of $1.0099 per share. After this transaction, the director beneficially owns 251,550 shares directly and 69,300 shares indirectly through a spouse. An additional 81,150 shares are held indirectly through the William M. Moore Trust and the Patricia A. Moore Trust, which hold the shares as tenants in common under trust agreements dated August 16, 2016 and August 17, 2016, respectively.
IRIDEX director William M. Moore reported buying 20,000 shares of IRIDEX common stock on 12/15/2025, shown as a purchase transaction.
The shares were acquired in multiple trades at weighted average prices between $0.98 and $0.9885 per share. Following this transaction, Moore directly owned 249,550 IRIDEX shares, with an additional 69,300 shares held indirectly by his spouse and 81,150 shares held indirectly through the William M. Moore Trust and the Patricia A. Moore Trust as tenants in common.